Table 6 Guiding principles in the management of ARV drug toxicity
{"Image DocumentName": "Table 6 Guiding principles in the management of ARV drug toxicity", "Image ImageDescription": "Determine the seriousness of the toxicity. Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV drug or drugs or to a non-ARV medication taken at the same time. Consider other disease processes (e.g. viral hepatitis in an individual on ARV drugs who develops jaundice) because not all problems that arise during treatment are caused by ARV drugs. Manage the adverse event according to severity. In general: Grade 4: Severe life-threatening reactions: Immediately discontinue all ARV drugs, manage the medical event (i.e. symptomatic and supportive therapy) and reintroduce ARV drugs using a modified regimen (i.e., with an ARV substitution for the offending drug) when the patient is stabilized. a. Grade 3: Severe reactions: Substitute the offending drug without stopping ART.a. Grade 2: Moderate reactions: Consider continuation of ART as long as feasible. If the patient does not improve on symptomatic therapy, consider single-drug substitutions.a. Grade1: Mild reactions are bothersome but do not require changes in therapy. Stress the maintenance of adherence despite toxicity for mild and moderate reactions. 6. If there is a need to discontinue ART because of life-threatening toxicity, all ARV drugs should be stopped until the patient is stabilized.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}